Key Details
Price
$5.25Annual ROE
-13.90%Beta
1.92Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 14, 2018Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The availability of Micro-Neighborhood ® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago.
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call.
The Company's AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program The Company's AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Conference Call on May 14, 2024 at 2:30 PM ET with Company Participants including CEO William Febbo, CFO Edward Stelmakh, President Steve Silvestro, and SVP of Corporate Finance Andrew D'Silva. Various conference call participants are also present. Thank you for joining the discussion on OptimizeRx's First Quarter Fiscal 2024 Earnings.
The average price target suggests a potential 34.8% increase for OptimizeRx (OPRX). Although studies show this metric may not always be accurate, an increase in earnings estimates could indicate a positive outlook for the stock in the short term.
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a top provider of healthcare technology solutions assisting life sciences companies in connecting with healthcare professionals (HCPs) and patients, disclosed today that its management will be attending the following upcoming investor conferences:
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FAQ
- What is the primary business of OptimizeRx?
- What is the ticker symbol for OptimizeRx?
- Does OptimizeRx pay dividends?
- What sector is OptimizeRx in?
- What industry is OptimizeRx in?
- What country is OptimizeRx based in?
- When did OptimizeRx go public?
- Is OptimizeRx in the S&P 500?
- Is OptimizeRx in the NASDAQ 100?
- Is OptimizeRx in the Dow Jones?
- When was OptimizeRx's last earnings report?
- When does OptimizeRx report earnings?
- Should I buy OptimizeRx stock now?